Provectus Pharmaceuticals Inc. (PVCT.OB) Initiates Recruitment for Phase II Efficacy Studies of its Metastatic Melanoma Treatment
Provectus Pharmaceuticals Inc. (OTCBB: PVCT) specializes in effective, affordable and minimally invasive oncology and dermatology therapies to treat diseases such as melanoma and psoriasis. The company today announced it is recruiting for its phase 2 clinical trials of PV-10 for the treatment of stage III and IV metastatic melanoma, the most deadly form of skin cancer. The company is focusing on recruiting 80 subjects at a fourth center in Adelaide, Australia to test the efficacy of PV-10. Throughout the next several months, Provectus expects to expand its study to incorporate subjects in other areas of Australia, as well as several…